businesspress24.com - Apotex Inc Voluntarily Recalls One Lot of Hypertension Medication Apo-Ramipril 5 mg
 

Apotex Inc Voluntarily Recalls One Lot of Hypertension Medication Apo-Ramipril 5 mg

ID: 1094125

(firmenpresse) - OTTAWA, ONTARIO -- (Marketwire) -- 03/19/12 -- The issue:

Health Canada is informing Canadians that Apotex Incorporated is conducting a voluntary recall of one lot of Apo-Ramipril 5mg Capsules used to treat hypertension (high blood pressure). The recall of Lot JR21798 was made to retail outlets across Canada.

Medication in the affected lot being recalled has been found to contain intact but empty capsules - meaning that patients taking them may not receive the dose of medication needed to treat their medical condition.

Without appropriate treatment, hypertension may lead to heart attack, stroke, kidney problems, internal bleeding and improper blood circulation. Although Apo-Ramipril is authorized for treatment of hypertension, the ingredient in this medication may also be prescribed for patients who have recently had a heart attack, or who are at high risk of heart attack or stroke.

Who is affected:

Canadians who have purchased the affected lot of Apo-Ramipril 5mg Capsules. Affected products bear the drug identification number (DIN 02251574) and are from Lot JR21798.

What consumers should do:

- Consult your healthcare practitioner if you have used this product or are concerned about your health.

- For information concerning the recall or how to return the affected product, consumers should directly contact Apotex Inc. at the following number 1-800-667-4708 or on .

- potentially related to this product to Health Canada.

- Submit complaints regarding the safety, efficacy or quality of health products, to Health Canada's Inspectorate, toll-free, at 1-800-267-9675.

What Health Canada is doing:

Health Canada is monitoring the voluntary recall of the product and informing Canadians of the risk. Should Health Canada become aware that this product remains available for sale in Canada, the Department will take appropriate action.

Background:





The company became aware of the issue when a customer complained. It found the same problem in some sample products retained by the manufacturer. Apotex initiated the recall of Lot JR21798 to retail outlets. Since the capsules of Apo-Ramipril 5 mg are not transparent, it may be difficult to determine whether a capsule from the affected lot is empty.

For more information:

Consumers and health professionals wanting more information about this advisory from Health Canada can contact the Public Enquiries Line at 613-957-2991, or toll free at 1-866-225-0709.

Media enquiries related to this Advisory should be directed to Health Canada Media Relations at 613-957-2983.

How to report side effects to health products:

To report suspected adverse reaction to these or other health products, please contact the Canada Vigilance Program of Health Canada toll-free at 1-866-234-2345, or complete a and send to us using one of these methods:

Stay connected with Health Canada and receive the latest advisories and product recalls using these social media tools:

Egalement disponible en francais



Contacts:
Media Inquiries:
Health Canada
613-957-2983

Public Inquiries:
613-957-2991
1-866-225-0709


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Consumer Advisory/Advertising on the Internet: Use of Media Advisory: Government of Canada to Announce Investments to Accelerate Automotive Sector Innovation
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 19.03.2012 - 10:52 Uhr
Sprache: Deutsch
News-ID 1094125
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

OTTAWA, ONTARIO


Phone:

Kategorie:

Government & Administration


Anmerkungen:


Diese Pressemitteilung wurde bisher 151 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Apotex Inc Voluntarily Recalls One Lot of Hypertension Medication Apo-Ramipril 5 mg
"
steht unter der journalistisch-redaktionellen Verantwortung von

Health Canada (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Health Canada



 

Who is online

All members: 10 568
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 70


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.